evidence varies by claim

Semax

Neurology, Aging & Mitochondria

Semax is indexed as peptide in the PeptideBase article library. It is referenced in “FDA Research Peptide Compounding Review: What It Is and What It Is Not” and 1 other PeptideBase article. This page groups the relevant coverage; evidence strength, safety, and clinical relevance depend on the specific claim and source.

Research status: evidence varies by claim

Deep Dives on Semax

Start here for the plain-English articles connected to this peptide.

research_other8 min read

FDA Panel Backed Six Peptides for Compounding—What the Vote Does (and Does Not) Mean

The FDA advisory panel backed 503A Bulks List inclusion for the free-base and acetate forms of six peptide groups and rejected emideltide/DSIP. Here is what the non-binding vote means—and what it does not prove.

Read article

Regulation & Evidence11 min read

FDA Research Peptide Compounding Review: What It Is and What It Is Not

A cautious explainer on FDA's July 2026 review of seven peptide-related bulk drug substances for the 503A Bulks List, why staff opposition matters, and why the review is not FDA approval or proof of safety.

Read article

Quick Facts

Origin: Named peptide referenced in PeptideBase coverage
Category: Neurology, Aging & Mitochondria

Research Areas